<DOC>
	<DOCNO>NCT03083041</DOCNO>
	<brief_summary>This multi-center , open-label , Phase II study intravenous ( IV ) SHR-1210 200mg , q2w combination Apatinib two dose level subject locally advanced metastatic non-small cell lung cancer ( NSCLC ) . The study compose two part . Part 1 study determine safety , tolerability pharmacokinetics SHR-1210 combination Apatinib . Part 2 include randomize comparison Apatinib 250mg/d 500mg/d plus SHR-1210 . Subject 's tumor screen baseline EGFR mutation , EML4-ALK translocation , PD-L1 expression.But positive tumor PD-L1 expression require enrollment .</brief_summary>
	<brief_title>A Study SHR-1210 Combination With Apatinib Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>SHR-1210 humanize monoclonal antibody Programmed death 1 ( PD-1 ) . Apatinib new kind selective Vascular Endothelial Growth Factor Receptor 2 ( VEGFR-2 ) tyrosine kinase inhibitor ( TKI ) . A disease-control rate 61.1 % mPFS 4.7 month show Apatinib phase II study patient NSCLC .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Subjects &gt; /= 18 year &lt; /=70 year age time Informed Consent . 2 . Advanced relapse refractory predominantly NSCLC least one measurable lesion accord RECIST 1.1 . 3 . Failure second line chemotherapy ( Part 1 ) ; Failure First line chemotherapy ( Part 2 ) 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 5 . Patients must recover AEs prior treatment randomization . 6 . Adequate bone marrow , liver renal function assess follow laboratory test conduct within 1 week randomization . HB ≥ 90g/L ; ANC≥1.5×10E+9/L ; PLT≥100×10E+9/L ; ALT AST &lt; 1.5×ULN ; TBIL ≤1×ULN ; Cr ≤1.5×ULN CL≥60 ml/min . 7 . Life expectancy least three month . 8 . Male female participant childbearing potential must willing use adequate method contraception start first dose study drug 60 day female subject 120 day male subject last dose study drug . 9 . Written inform consent willingness ability comply aspects protocol . 1 . Suffered grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia ( include QT interval male ≥ 450 m , female≥ 470 m ) . 2 . Severe uncontrolled systemic disease clinically significant hypertension ( systolic pressure &gt; /= 140 mm Hg and/or diastolic pressure &gt; /= 90 mm Hg ) , Grade IIIIV cardiac insufficiency , accord NYHA criterion echocardiography check : LVEF &lt; 50 % . 3 . Factors affect oral administration ( inability swallow tablet , GI tract resection , chronic bacillary diarrhea intestinal obstruction ) . 4 . Coagulation disfunction , hemorrhagic tendency receive anticoagulant therapy 5 . &gt; /= CTCAE 2 pneumorrhagia &gt; /= CTCAE 3 hemorrhage organ within 4 week . 6 . Bone fracture wound cure . 7 . Arterial thrombus phlebothrombosis within 6 month take anticoagulant agent . 8 . Mental disease psychotropic substance abuse . 9 . Previous treatment trial agent within 4 week 10 . Proteinuria ≥ ( ++ ) 24 hour total urine protein &gt; 1.0 g. 11 . Other coexist malignant disease ( except basalcell carcinoma carcinoma situ uterine cervix ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SHR-1210</keyword>
	<keyword>Apatinib</keyword>
	<keyword>NSCLC</keyword>
</DOC>